Vertex Pharmaceuticals Incorporated
VRTX
$388.25
-$6.87-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.28% | 2.59% | 15.66% | 11.61% | 6.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.06% | 2.96% | 15.66% | 11.61% | 6.11% |
| Cost of Revenue | 8.12% | 18.64% | 5.41% | 12.39% | -57.14% |
| Gross Profit | 12.91% | -8.43% | 24.89% | 10.97% | 55.59% |
| SG&A Expenses | 14.08% | 15.67% | -6.53% | 40.94% | 41.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.83% | 17.95% | 2.59% | 17.80% | 26.07% |
| Operating Income | 23.46% | -15.22% | 37.02% | 3.72% | -17.72% |
| Income Before Tax | 137.83% | -42.90% | -0.97% | 3.81% | -391.97% |
| Income Tax Expenses | 23.57% | -53.15% | 25.00% | 24.18% | -17.66% |
| Earnings from Continuing Operations | 128.74% | -41.22% | -5.76% | 0.98% | -492.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 128.74% | -41.22% | -5.76% | 0.98% | -492.44% |
| EBIT | 23.46% | -15.22% | 37.02% | 3.72% | -17.72% |
| EBITDA | 21.94% | -14.98% | 32.70% | 4.56% | -16.03% |
| EPS Basic | 128.90% | -40.93% | -5.69% | 0.97% | -491.83% |
| Normalized Basic EPS | 20.13% | -15.19% | 27.15% | -0.14% | -15.27% |
| EPS Diluted | 128.66% | -40.86% | -5.64% | 1.01% | -495.55% |
| Normalized Diluted EPS | 19.11% | -15.09% | 27.25% | -0.29% | -14.39% |
| Average Basic Shares Outstanding | -0.54% | -0.50% | -0.08% | 0.00% | 0.16% |
| Average Diluted Shares Outstanding | 0.31% | -0.61% | -0.15% | 0.15% | -0.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |